GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Clinical trials for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail aims to wipe out stomach cancer before surgery
Disease control Not yet recruitingThis study tests a combination of an experimental drug (IBI343), an immunotherapy (sintilimab), and chemotherapy (SOX) given before and after surgery for people with a specific type of advanced stomach or gastroesophageal junction cancer. The goal is to see if this approach can c…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated May 16, 2026 23:53 UTC
-
New hope for advanced stomach cancer: targeted drug enters final testing phase
Disease control Not yet recruitingThis study tests a new drug called BL-M05D1 in people with advanced stomach or gastroesophageal junction cancer that has a specific marker (CLDN18.2) and has stopped responding to initial treatment. About 438 adults will be randomly assigned to receive either BL-M05D1 or a standa…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 16, 2026 23:37 UTC
-
New injection plus chemo aims to wipe out stomach cancer before surgery
Disease control Not yet recruitingThis study tests whether injecting a new treatment called RP2 directly into stomach or esophageal tumors, along with standard chemotherapy (FLOT), is safe and works better than chemo alone before surgery. About 34 people with stage 2 or higher non-metastatic cancer will take part…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
New triple therapy shows promise for hard-to-treat stomach cancer
Disease control Not yet recruitingThis study is for people with advanced HER2-negative stomach or gastroesophageal junction cancer that cannot be removed by surgery. It tests a new approach: giving a special type of radiotherapy followed by a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) p…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE4 • Sponsor: Huazhong University of Science and Technology • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
New hope for advanced stomach cancer: drug combo targets tumors after standard therapy fails
Disease control Not yet recruitingThis study tests whether a combination of two immunotherapy drugs (Iparomlimab and Tuvonralimab) plus chemotherapy can help people with advanced stomach or gastroesophageal junction cancer whose first treatment stopped working. About 30 adults aged 18-75 will receive the drug com…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: NA • Sponsor: Qingxia Li • Aim: Disease control
Last updated May 11, 2026 20:49 UTC
-
Experimental pill tested on patients with advanced cancers
Disease control Not yet recruitingThis is the first human study of an experimental oral drug called ACC-1898 for adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and understand how the body processes the drug. Participants will take dail…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1 • Sponsor: AccSalus Biosciences, Inc. • Aim: Disease control
Last updated Apr 21, 2026 12:44 UTC